MergerJul 29, 2026, 04:28 PM
MiMedx to Acquire Sanara MedTech for $35/Share, $350M EV
AI Summary
MiMedx Group, Inc. announced its definitive agreement to acquire Sanara MedTech Inc. in a cash and stock transaction valued at $35 per Sanara share, totaling approximately $350 million in enterprise value. The acquisition is expected to create a leading regenerative medicine company, significantly expand MiMedx's surgical footprint, and be immediately accretive to its financial profile. The combined entity anticipates over $20 million in run-rate cost synergies and expects 2027 total revenue to exceed $400 million with an Adjusted EBITDA margin over 20%.
Key Highlights
- MiMedx to acquire Sanara MedTech for $35.00 per share.
- Total enterprise value of the transaction is approximately $350 million.
- Consideration includes $33.00 cash and 0.4735 shares of MiMedx common stock per Sanara share.
- The offer represents a 46% premium to Sanara's 30-day volume-weighted average share price.
- Expected to be immediately accretive to MiMedx's revenue growth, gross margin, and Adjusted EBITDA margin.
- Anticipates over $20 million in run-rate cost synergies.
- Combined 2027 total revenue expected to exceed $400 million with over 20% Adjusted EBITDA margin.
- Cash portion financed by cash on hand and a new $300 million term loan.
- Transaction unanimously approved by both boards and expected to close by year-end.
Price Impact
More from SMTI